Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobocter pylori eradication: 7 vs. 14 day treatment

Helicobacter

Volumn 9, Issue 5, 2004, Pages 417-421

  Bosques Padilla, Francisco J ^a   Garza González, Elvira ^b   Calderón Lozano, Irma E ^a   Reed SanRoman, Gerardo ^c   De Ariño Suárez, Mauricio ^c   Valdovinos Díaz, Miguel Á ^c   Orozco Gámiz, Antonio ^c   Blancas Valencia, Juan M ^c   Tamayo De La Cuesta, José L ^c  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^c Hosp Univ Dr J Eleuterio Gonzalez ^*  (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; OFLOXACIN; RABEPRAZOLE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DYSPEPSIA; ERADICATION THERAPY; FEMALE; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MEXICO; MIDDLE AGED; OFLOXACIN; OMEPRAZOLE; TIME FACTORS; TREATMENT OUTCOME;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 4644227740     PISSN: 10834389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1083-4389.2004.00265.x     Document Type: Article

References (16)

1. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
2. Perri F, Qasim A, Marras L, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2003;8(suppl 1):S53-S60.
3. Van Oijen AH, Verbeek AL, Jansen JB, de Boer WA. Review article. Treatment of Helicobacter pylori infection with ranitidine bismuth citrate-or proton pump inhibitor-based triple therapies. Aliment Pharmacol Ther 2000;14:991-9.
4. Pipkin GA, Williamson R, Wood JR. Review article. One week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1998;12:823-37.
5. Kearney DJ. Retreatment of Helicobacter pylori infection after initial treatment failure. Am J Gastroenterol 2001;96:1335-9.
6. Perri F, Festa V, Clemente R, Villani MR, Quitadamo M, Caruso N, Bergoli ML, Andriulli A. Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96:58-62.
7. Chan FK, Sung JJ, Suen R, Wu JC, Ling TK, Chung SC. Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. Aliment Pharmacol Ther 2000;14:91-5.
8. Gisbert JP, Gisbert JL, Marcos S, Gravalos RG, Carpio D, Pajares JM. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999;13:1311-6.
9. Lamouliatte H, Megraud F, Delchier JC, et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003;18:791-7.
10. Megraud F, Lamouliatte H. Review article. The treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:1333-43.
11. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003;18:627-33.
12. Megraud F. Strategies to treat patients with antibiotic resistant Helicobacter pylori. Int J Antimicrob Agents 2001;16:507-9.
13. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:1339-43.
14. Flores-Orta D, Bosques-Padilla F, Gómez-Leija G, Frederick F. Comparative study of rapid urease test (Hazell test) vs CLO-test in the diagnosis of Helicobacter pylori infection. Gut 1997;41(Suppl 3):A160.
15. Perri F, Festa V, Merla A, Barberani F, Pilotto A, Andriulli A. Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2003;18:815-20.
16. Garza-Gonzalez E, Perez-Perez GI, Alanis-Aguilar O, Tijerina-Menchaca R, Maldonado-Garza HJ, Bosques-Padilla FJ. Antibiotic susceptibility patterns of Helicobacter pylori strains isolated from northeastern Mexico. J Chemother 2002;14:342-5.